Institute Of Cancer Research, United Kingdom

This study tests whether a combination of antibiotics can make the hormone therapy enzalutamide more effective for men with metastatic castration-resistant prostate cancer (mCRPC). About 39 participants will receive two weeks of amoxicillin and metronidazole, then two weeks of ci…

This early-phase study tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can make cancer cells more visible to the immune system…

This study tests whether adding an experimental drug called SX-682 to the standard drug apalutamide can help men with a tough-to-treat type of advanced prostate cancer (metastatic castration-resistant prostate cancer). The goal is to find a safe dose that also reduces certain imm…

This trial tests two experimental drugs, avutometinib and defactinib, alone or with chemotherapy, in people with high-grade brain tumours like glioblastoma. The goal is to see if the combination is safe and can shrink tumours or slow their growth. About 182 adults whose tumours h…

This study tests if injecting a very dilute hydrogen peroxide solution into breast tumors can make standard radiotherapy work better. It is for people with advanced or returning breast cancer. The treatment, called KORTUC, is given twice a week during radiotherapy and aims to shr…

This study tests a new drug called paxalisib combined with standard chemotherapy (temozolomide) in people with aggressive brain tumours like glioblastoma. The goal is to see if the combination is safe and can help control the tumour for longer. About 64 adults with newly diagnose…

This study compares a new PET-CT scan (FCH-PET-CT) to standard imaging (bone scan and MRI/CT) to see which better finds cancer that has spread outside the pelvis in men with prostate cancer and specific DNA repair gene mutations. About 50 men with these mutations will be enrolled…

This study follows 200 men with prostate cancer who are on active surveillance (monitoring instead of immediate treatment). It compares those with higher genetic risk to those with average risk to see if their cancer progresses differently. The goal is to understand how genes and…

This study is testing a new saliva-based DNA test called i4i PRODICT® that estimates a person's future risk of prostate cancer. Researchers want to see how well the test works in men of Black African/Caribbean, South Asian, and White backgrounds. The study will recruit 1000 men a…

This study looks at whether a genetic test can help predict prostate cancer risk in men who have or are at high risk for the disease. Researchers will analyze DNA from 3000 men to find rare and common genetic changes linked to prostate cancer. The goal is to see if this informati…

This study follows men with prostate cancer who have rare gene mutations (like BRCA) and compares them to men without these mutations. Researchers collect medical data and tumor samples to see if the mutations affect survival and cancer spread. The goal is to guide better treatme…